Streetbeat News

Products Services

AZN

AstraZeneca has announced that Airsupra, a combination of albuterol and budesonide, is now available by prescription in the U.S. for the as-needed treatment or prevention of asthma symptoms in adults. The FDA approved Airsupra in January 2023 for individuals aged 18 and older.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:08 pm

DOGEUSD

FLOKIUSD

Dogecoin (DOGE) experienced a surge of over 10% following buzz around a payment feature on Elon Musk's 'everything app' X. A verified account for X Payments has been created, fueling rumors that DOGE will be used as a universal payment method on the platform. Analyst Johnny predicts DOGE could reach $0.10, while Peppe has added DOGE to his portfolio due to these speculations. Interest in similar coins like FLOKI is also expected to rise, with FLOKI's market value increasing from $266 million to $300 million. Despite the excitement, Dogecoin's price fell 4%, with significant liquidations occurring.

Portfolio Pulse from Mehab Qureshi

January 22, 2024 | 12:07 pm

AUTL

Autolus Therapeutics plc (NASDAQ:AUTL) has announced that the FDA accepted its BLA for obecabtagene autoleucel (obe-cel), a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL). The FDA has set a PDUFA target action date of November 16, 2024, and does not plan to hold an advisory committee meeting on the application.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:07 pm

AAPL

Apple Inc. (AAPL) has opened pre-orders for its Vision Pro mixed reality headset, with accessories and support plan totaling $1,510. The cost of essential accessories and AppleCare+ is $1,200, equivalent to the price of an iPhone 15 Pro Max. Analyst Ming-Chi Kuo reports better than expected demand for Vision Pro, with sales between 160,000 to 180,000 units, but warns of potential demand drop-off. Jim Cramer expressed skepticism about the product's broad appeal due to its high price.

Portfolio Pulse from Rounak Jain

January 22, 2024 | 12:04 pm

PHVS

The FDA has removed the clinical hold on Pharvaris' Investigational New Drug (IND) application for deucrictibant, a prophylactic treatment for hereditary angioedema attacks. This decision was made after reviewing data from a 26-week rodent toxicology study.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 11:52 am

NIO

Nio Inc. (NYSE:NIO) has launched a battery-sharing program for the Chinese New Year travel period, encouraging owners to swap their 100-kWh batteries for 70/75-kWh ones. Participants will earn Nio Credits and Points from Jan. 20 to Feb. 20, with increased rewards for consistent participation. The initiative aims to address the high demand for travel during the holidays and promote the use of Nio's battery swap technology.

Portfolio Pulse from Anan Ashraf

January 22, 2024 | 11:46 am

GIB

CGI (NYSE:GIB), a leading business and IT consulting firm, has announced a global partnership with Körber to enhance production operations for pharmaceutical and life sciences clients. The collaboration integrates CGI's comprehensive services with Körber's Werum PAS-X MES Suite, aiming to boost efficiency, accuracy, and safety in pharmaceutical production, as well as improve decision-making with real-time data access.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 11:38 am

NGL

NGL Energy Partners LP (NYSE:NGL) announced the expansion of its Lea County Express Pipeline System, increasing capacity from 140,000 to 340,000 barrels of water per day by 2024. The LEX II Expansion includes a new 27-mile pipeline and additional facilities, supported by a contract with an investment grade oil and gas producer.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 11:33 am

BNOX

Bionomics has announced positive Phase 2b data for BNC210 in treating PTSD, with an FDA discussion expected in Q2'24. They also reported a successful End of Phase 2b meeting with the FDA for BNC210 in SAD, following positive Phase 2 trial results. The company is currently in talks for strategic partnerships for its pipeline assets and is considering clinical development plans for BNC210 in both PTSD and SAD.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 11:04 am

META

MSFT

Nightshade, a free tool developed by the University of Chicago, allows artists to use 'data poisoning' to protect their copyrighted images from being used by AI image generators. The tool subtly alters images to disrupt AI training without affecting human perception. This comes amid concerns over AI misuse, highlighted by Scarlett Johansson's lawsuit against an AI generator and the launch of new AI image generators by Meta Platforms Inc. and Microsoft Corp.-backed OpenAI.

Portfolio Pulse from Rounak Jain

January 22, 2024 | 10:54 am